Integrilin and Ventricular tachycardia - a phase IV clinical study of FDA data

Summary:

Ventricular tachycardia is reported as a side effect among people who take Integrilin (eptifibatide), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Heparin, and have Coronary heart disease.

The phase IV clinical study analyzes which people have Ventricular tachycardia when taking Integrilin. It is created by eHealthMe based on reports of 3,029 people who have side effects when taking Integrilin from the FDA, and is updated regularly.

What is Integrilin?

Integrilin has active ingredients of eptifibatide. eHealthMe is studying from 3,037 Integrilin users. Check the latest studies of Integrilin.

What is Ventricular tachycardia?

Ventricular tachycardia (rapid heartbeat that originates in one of the lower chambers (the ventricles) of the heart) is found to be associated with 1,290 drugs and 2,096 conditions by eHealthMe. Check the latest studies of Ventricular tachycardia.

On Jul, 12, 2026

3,029 people reported to have side effects when taking Integrilin.
Among them, 30 people (0.99%) have Ventricular tachycardia.

Could Integrilin cause Ventricular tachycardia?

Among these 30 people:

How long have people been on Integrilin when they have Ventricular tachycardia? *

What is the gender of people who have Ventricular tachycardia when taking Integrilin? *

female: 40 %
male: 60 %

What is the age of people who have Ventricular tachycardia when taking Integrilin? *

What are other drugs people take besides Integrilin? *

What are other side effects people have besides Ventricular tachycardia? *

Hypotension (abnormally low blood pressure): 10 people, 33.33%
Heart Attack: 7 people, 23.33%
Thrombocytopenia (decrease of platelets in blood): 7 people, 23.33%
Chest Pain: 7 people, 23.33%
Cardiac Arrest: 7 people, 23.33%
Cardiogenic Shock (inadequate circulation of blood): 6 people, 20.00%
Haematuria (presence of blood in urine): 5 people, 16.67%
Cardio-Respiratory Arrest (sudden dysfunction of heart and lungs): 5 people, 16.67%
Ventricular Fibrillation (abnormally irregular heart rhythm): 5 people, 16.67%
Fatigue (feeling of tiredness): 4 people, 13.33%

What are the existing conditions these people have? *

Coronary Heart Disease (narrowing or blockage of the coronary arteries): 3 people, 10.00%
Acute Myocardial Infarction (acute heart attack): 2 people, 6.67%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 6.67%
Back Pain: 2 people, 6.67%
High Blood Pressure: 2 people, 6.67%
High Blood Cholesterol: 2 people, 6.67%
Heart Attack: 2 people, 6.67%
Cardiac Failure Congestive: 2 people, 6.67%
Chest Pain: 1 person, 3.33%
Allergic Rhinitis: 1 person, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Integrilin and have Ventricular tachycardia?

- Check whether Ventricular tachycardia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Integrilin:

Integrilin (3,037 reports)

Browse all side effects of Integrilin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Ventricular tachycardia:

Ventricular tachycardia (1,290 drugs)

Browse all the conditions that are associated with Ventricular tachycardia:

Ventricular tachycardia (2,096 conditions)

Related publications that referenced our studies

Amit K J Mandal, Umar F Khan, Constantinos G Missouris, "Ventricular tachycardia in a patient with sigmoid volvulus on treatment with donepezil", Clinical Toxicology, 2019 Jan .
Amit K J Mandal, Umar F Khan, Constantinos G Missouris, "Ventricular tachycardia in a patient with sigmoid volvulus on treatment with donepezil", Clinical Toxicology, 2019 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on eptifibatide (the active ingredients of Integrilin) and Integrilin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.